Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

Trial Profile

A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Chondrosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2019 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
    • 19 Jul 2019 Results from cohort of patients with advanced extraskeletal myxoid chondrosarcoma (n=26; data cutoff Oct 9, 2018) published in the Lancet Oncology
    • 04 Jun 2019 Results (n=34) assessing outcomes of typical solitary fibrous tumors (T-SFT) cohort, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top